Clinical Trial Update: LDL-Cholesterol Lowering Effect of KB2115 as Add on to Statin [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating KB2115 as an add-on to statin therapy for lowering LDL-cholesterol in dyslipidemia; the study provides an update on its LDL-lo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia

Drugs mentioned

• KB2115

Snippet

Sponsor: Karo Bio AB | Conditions: Dyslipidemia | Phase 2 | Status: COMPLETED